Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wilhelmsson

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Scandinavian Cardiovascular Journal : SCJ|September 13, 2000
Who determines the research agenda?--IIC Wilhelmsson
Science (New York, N.Y.)|March 11, 2000
Clarificatioin of AstraZeneca's R&D strategiesC Wilhelmsson
Acta Medica Scandinavica. Supplementum|January 1, 1975
Laboratory analyses during two years' treatment with alprenolol in patients with myocardial infarctionC Wilhelmsson, A Vedin
Lakartidningen|February 22, 1984
[Difficulties in connection with and evaluation of clinical trials]A Vedin, C Wilhelmsson
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|January 1, 1986
The effect and usefulness of early intravenous beta blockade in acute myocardial infarctionA Vedin, C Wilhelmsson
The American Journal of Cardiology|July 20, 1983
Beta blockers in ischemic heart diseaseC Wilhelmsson, A Vedin
Acta Medica Scandinavica. Supplementum|January 1, 1981
Beta blockers after myocardial infarction--aspects on study design based on current knowledgeA Vedin, C Wilhelmsson
European Heart Journal|January 1, 1985
Medical treatment of ischaemic heart disease--beta-blockersA Vedin, C Wilhelmsson
European Journal of Clinical Pharmacology|November 1, 1979
Effects of labetalol and propranolol on blood pressure at rest and during isometric and dynamic exerciseG Nyberg, A Vedin, C Wilhelmsson
Acta Medica Scandinavica. Supplementum|January 1, 1981
Methodological aspects in the design of secondary prevention trialsC Wilhelmsson, A Vedin, H Wedel
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Scandinavian Cardiovascular Journal : SCJ|September 13, 2000
Who determines the research agenda?--IIC Wilhelmsson
Science (New York, N.Y.)|March 11, 2000
Clarificatioin of AstraZeneca's R&D strategiesC Wilhelmsson
Acta Medica Scandinavica. Supplementum|January 1, 1975
Laboratory analyses during two years' treatment with alprenolol in patients with myocardial infarctionC Wilhelmsson, A Vedin
Lakartidningen|February 22, 1984
[Difficulties in connection with and evaluation of clinical trials]A Vedin, C Wilhelmsson
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|January 1, 1986
The effect and usefulness of early intravenous beta blockade in acute myocardial infarctionA Vedin, C Wilhelmsson
The American Journal of Cardiology|July 20, 1983
Beta blockers in ischemic heart diseaseC Wilhelmsson, A Vedin
Acta Medica Scandinavica. Supplementum|January 1, 1981
Beta blockers after myocardial infarction--aspects on study design based on current knowledgeA Vedin, C Wilhelmsson
European Heart Journal|January 1, 1985
Medical treatment of ischaemic heart disease--beta-blockersA Vedin, C Wilhelmsson
European Journal of Clinical Pharmacology|November 1, 1979
Effects of labetalol and propranolol on blood pressure at rest and during isometric and dynamic exerciseG Nyberg, A Vedin, C Wilhelmsson
Acta Medica Scandinavica. Supplementum|January 1, 1981
Methodological aspects in the design of secondary prevention trialsC Wilhelmsson, A Vedin, H Wedel
Pageof 11